<DOC>
	<DOCNO>NCT01824056</DOCNO>
	<brief_summary>The objective protocol analyze sensitivity specificity 18F-DTBZ PET differential diagnosis Parkinson 's disease ( PD ) parkinsonism disorder , include multiple system atrophy ( MSA ) , corticobasal degeneration ( CBD ) , progressive supranuclear palsy ( PSP ) .</brief_summary>
	<brief_title>The Differential Diagnosis Parkinson 's Disease Parkinsonism Positron-emission Tomography</brief_title>
	<detailed_description>40 patient PD , 40 patient MSA , 20 patient CBD , 20 patient PSP , enrol . Each evaluable subject involve study must fulfill inclusion exclusion criterion accord subject grouping , subject 3 visit study , one screening visit , one imaging visit , one safety evaluation visit . Safety measurement evaluate medical history , vital sign , physical examination ,</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>1 . Forty subject diagnosis PD must : i.Male female patient , age range 20~80 . ii.Patients fulfil Criteria diagnosis Parkinson disease8 `` possible '' `` probable '' PD ( Appendix I ) . iii.Patients provide write informed consent prior study entry . If patient incapable informed consent , caregiver may consent behalf patient ( patient must still confirm assent ) . 2 . Forty subject diagnosis MSA must : i.Male female patient , age range 20~80 . ii.Patients fulfil Consensus diagnostic criterion `` possible '' `` probable '' MSA14 ( Appendix II ) . iii . Patients provide write informed consent prior study entry . If patient incapable informed consent , caregiver may consent behalf patient ( patient must still confirm assent ) . 3 . Twenty subject diagnosis PSP must : i.Male female patient , age range 20~80 . ii.Patients fulfil NINDSSPSP clinical criterion diagnosis PSP `` possible '' `` probable '' PSP35 ( Appendix III ) . iii.Patients provide write informed consent prior study entry . If patient incapable informed consent , caregiver may consent behalf patient ( patient must still confirm assent ) . 4 . Twenty subject diagnosis CBD must : i.Male female patient , age range 20~80 . ii.Patients fulfil Kumar 's criterion CBD36 ( Appendix IV ) . iii.Patients provide write informed consent prior study entry . If patient incapable informed consent , caregiver may consent behalf patient ( patient must still confirm assent ) . 1 . Pregnant become pregnant study current breast feeding . 2 . Any subject clinically significant abnormal laboratory value , and/or clinically significant unstable medical psychiatric illness . i.Clinically significant hepatic , renal , pulmonary , metabolic , endocrine disturbance . ii.Current clinically significant cardiovascular disease . ( cardiac surgery myocardial infarction within last 6 month ; unstable angina ; decompensated congestive heart failure ; significant cardiac arrhythmia ; congenital heart disease . 3 . History drug alcohol abuse within last year , prior prolonged history abuse . 4 . History presence QTc prolongation . 5 . History intracranial operation , include thalamotomy , pallidotomy , and/or deep brain stimulation . 6 . Any documented abnormality brain CT MRI brain , might contribute motor function , hydrocephalus , multiple infarction encephalomalacia , exclude . Mild cortical atrophy nonspecific white matter change allow . 7 . Patients evidence secondary parkinsonism ( multiple infarct , intoxication , hydrocephalus , etc ) neurodegenerative disease , spinocerebellar atrophy ( SCA ) , Wilson 's disease , hydrocephalus , multiple infarction , serious head injury definite history neurotoxin exposure , exclude . 8 . General PET exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>18F-FDG</keyword>
</DOC>